Update on dermatomyositis
Issued Date
2022-10-01
Resource Type
ISSN
13507540
eISSN
14736551
Scopus ID
2-s2.0-85137745729
Pubmed ID
35942671
Journal Title
Current Opinion in Neurology
Volume
35
Issue
5
Start Page
611
End Page
621
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Opinion in Neurology Vol.35 No.5 (2022) , 611-621
Suggested Citation
Tanboon J. Update on dermatomyositis. Current Opinion in Neurology Vol.35 No.5 (2022) , 611-621. 621. doi:10.1097/WCO.0000000000001091 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85497
Title
Update on dermatomyositis
Author(s)
Other Contributor(s)
Abstract
Purpose of reviewThis review summarizes and comments on current knowledge in dermatomyositis.Recent findingsThe 2018 European Neuromuscular Centre classification of dermatomyositis has been challenging by the discovery of clinicopathological features associated with dermatomyositis-specific antibody (DMSA) that were not incorporated in the original criteria. These features include but may not be limited to the presence of perifascicular necrosis in anti-Mi-2 dermatomyositis; presence of diffuse nonperifascicular sarcoplasmic myxovirus resistance protein A expression in anti-MDA5 dermatomyositis; and dermatomyositis sine dermatitis in anti-NXP-2 dermatomyositis. Variations and subclassifications within the same DMSA subtypes are observed: anti-MDA5 dermatomyositis is clinically subcategorized into good, intermediate, and poor prognostic subgroups; concurrent anti-CCAR1 and anti-TIF1-γ positivity identify anti-TIF1-γ-positive patient with a lower risk for cancer-associated myositis. Owing to distinct IFN1-signaling pathway activation in dermatomyositis, JAK-STAT inhibitor - the pathway-targeted therapy, have been studied with promising results in refractory dermatomyositis and some new-onset dermatomyositis. In addition, the potential serum biomarkers for IFN1 pathway activation are being investigated for their performance in monitoring the disease activity and the efficacy of the treatment.SummaryDMSA, evidence of prominent IFN1 pathway activation, and risk/severity-associated biomarkers would likely play major roles in future dermatomyositis classification, disease monitoring, and treatment decision.